1. Home
  2. USFD vs INCY Comparison

USFD vs INCY Comparison

Compare USFD & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo US Foods Holding Corp.

USFD

US Foods Holding Corp.

HOLD

Current Price

$86.80

Market Cap

18.8B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$101.71

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USFD
INCY
Founded
2007
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Food Distributors
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8B
17.0B
IPO Year
2016
1993

Fundamental Metrics

Financial Performance
Metric
USFD
INCY
Price
$86.80
$101.71
Analyst Decision
Strong Buy
Buy
Analyst Count
10
20
Target Price
$89.70
$97.78
AVG Volume (30 Days)
2.7M
2.0M
Earning Date
02-12-2026
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
2.09
3878.02
EPS
2.38
5.90
Revenue
$39,115,000,000.00
$4,813,105,000.00
Revenue This Year
$6.50
$19.64
Revenue Next Year
$6.20
$10.98
P/E Ratio
$36.87
$17.10
Revenue Growth
4.80
18.09
52 Week Low
$57.36
$53.56
52 Week High
$88.32
$112.29

Technical Indicators

Market Signals
Indicator
USFD
INCY
Relative Strength Index (RSI) 64.20 48.35
Support Level $82.51 $99.28
Resistance Level $88.32 $104.41
Average True Range (ATR) 2.22 3.12
MACD 0.32 -0.47
Stochastic Oscillator 76.38 29.50

Price Performance

Historical Comparison
USFD
INCY

About USFD US Foods Holding Corp.

US Foods Holding Corp is the U.S. food service distributor that distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. It has nearly 250,000 restaurants and foodservice operators with more than 70 locations that provide customers with food offering and a comprehensive suite of e-commerce, technology, and business solutions. The company operates in one business segment in which it markets, sells and distributes fresh, frozen and dry food and non-food products to foodservice customers throughout the U.S.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: